Filing Analysis
Curis, Inc. has regained compliance with Nasdaq's Bid Price Rule and the terms of a previous Hearings Panel decision. However, the company is now subject to a one-year Discretionary Panel Monitor period during which any further non-compliance will result in immediate delisting proceedings without the ability to submit a new compliance plan.
🚩 Red Flags
- One-year Discretionary Panel Monitor status indicates a history of non-compliance.
- Strict limitations on remedial actions: Staff will not grant additional time or accept new compliance plans if another deficiency occurs during the monitor period.
- Risk of immediate Delist Determination Letter upon any further violation.
📋 Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule).
- In full compliance with terms set forth by the Nasdaq Hearings Panel as of July 24, 2026.
- Subject to a Discretionary Panel Monitor for one year starting July 24, 2026.
- Under the monitor period, the company cannot provide new plans of compliance for any deficiencies that arise.
Curis, Inc. has implemented a 1-for-20 reverse stock split effective July 2, 2026. The split aims to consolidate shares and will result in adjusted trading for the 'CRIS' ticker starting July 6, 2026.
🚩 Red Flags
- Reverse stock split (typically used to combat low share prices or avoid delisting).
📋 Key Facts
- A 1-for-20 reverse stock split was filed with the Secretary of State of Delaware on July 2, 2026.
- Every 20 shares of Common Stock will be converted into one share of Common Stock.
- Fractional shares will be rounded up to the nearest whole share.
- Warrants, restricted stock units, and stock options will be adjusted accordingly in both quantity and exercise price.
- Trading on a split-adjusted basis is scheduled to begin at the opening of trading on July 6, 2026.
- The ticker symbol 'CRIS' remains unchanged.
Curis, Inc. has announced the expected effective date for its reverse stock split, which is scheduled to take effect on July 2, 2026, at 5:00 PM ET.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq compliance or mitigate low share price).
📋 Key Facts
- Reverse stock split becomes effective on July 2, 2026, at 5:00 PM ET.
- Common stock will begin trading on a split-adjusted basis on July 6, 2026.
- The ticker symbol 'CRIS' remains unchanged.
- New CUSIP number for common stock is 231269408.
Curis, Inc. stockholders approved a reverse stock split during a special meeting on June 25, 2026. Following this approval, the Board exercised its discretion to implement a 1-for-20 reverse stock split of all issued and outstanding common stock.
🚩 Red Flags
- Implementation of a reverse stock split is often used to regain compliance with Nasdaq minimum bid price requirements (typically $1.00), suggesting potential delisting risk.
- Reverse splits can be perceived by the market as a sign of distress or lack of organic share price appreciation.
📋 Key Facts
- Special Meeting held on June 25, 2026.
- Stockholders approved amendments to the Restated Certificate of Incorporation for a reverse stock split ratio between 1-for-5 and 1-for-25.
- The Board officially implemented a 1-for-20 reverse stock split on June 25, 2026.
Curis, Inc. stockholders have approved a proposal to implement a reverse stock split with a ratio between 1-for-5 and 1-for-25. This decision follows a special meeting held on June 25, 2026.
🚩 Red Flags
- Reverse stock split implementation is often a defensive measure to maintain Nasdaq listing compliance regarding minimum bid price requirements.
- Significant 'Against' and 'Abstain' votes relative to total shares cast may indicate shareholder dissatisfaction with capital structure changes.
📋 Key Facts
- Stockholders approved Proposal 1: A reverse stock split with a ratio ranging from 1-for-5 to 1-for-25, as determined by the Board of Directors.
- The vote for Proposal 1 resulted in 26,898,163 votes 'For', 751,966 'Against', and 123,820 'Abstain'.
- Proposal 2 (to adjourn the meeting to solicit more proxies) was approved but deemed unnecessary as Proposal 1 passed.
- The Board retains discretion over the specific ratio within the approved range.
Curis, Inc. stockholders approved an amendment to double the company's authorized common stock from approximately 283.8 million to 567.5 million shares. Additionally, the company eliminated its Series A and Series B Preferred Stock designations, returning them to unissued status.
🚩 Red Flags
- Significant increase in authorized shares (100% increase) creates substantial potential for future equity dilution.
- Multiple 8-K items (3.03, 5.03, 5.07) triggered in a single filing.
📋 Key Facts
- Authorized capital stock increased from 288,757,150 to 572,514,300 shares on May 19, 2026.
- Authorized common stock increased from 283,757,150 to 567,514,300 shares, representing a 100% increase.
- Filed a Certificate of Elimination for Series A Convertible Exchangeable Preferred Stock and Series B Convertible Non-Redeemable Preferred Stock.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Curis, Inc. reported its financial results for the first quarter ended March 31, 2026, via a press release furnished with the SEC.
📋 Key Facts
- The filing reports financial results for the three-month period ended March 31, 2026.
- The report was filed on May 12, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The full press release is included as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Curis, Inc. received a Delist Determination Letter from Nasdaq on April 27, 2026, after failing to maintain the $1.00 minimum bid price requirement. Because the company was already under a one-year Discretionary Panel Monitor, it is not eligible for a standard cure period and faces immediate suspension of trading on May 6, 2026, pending an appeal.
🚩 Red Flags
- Imminent delisting and suspension of trading on the Nasdaq Capital Market.
- Loss of standard compliance/cure periods due to existing 'Discretionary Panel Monitor' status.
- Persistent failure to maintain a $1.00 share price.
- The company must now succeed in a formal hearing to avoid moving to over-the-counter (OTC) markets.
📋 Key Facts
- Received Delist Determination Letter from Nasdaq Staff on April 27, 2026.
- Common stock bid price closed below $1.00 for 30 consecutive business days.
- Company is currently subject to a one-year Discretionary Panel Monitor effective February 3, 2026.
- Trading suspension is scheduled for May 6, 2026, unless a hearing is requested by May 4, 2026.
- The company intends to appeal the determination to the Nasdaq Hearings Panel to stay the delisting.
Curis, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished with the filing on March 19, 2026.
📋 Key Facts
- Reporting period covers the three and twelve months ended December 31, 2025.
- The announcement was made on March 19, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
Curis, Inc. stockholders approved a massive increase in authorized common stock from approximately 68.3 million to 283.8 million shares and authorized the issuance of shares related to Series B Preferred Stock and various warrants. The meeting also resulted in the approval of a new 2026 Incentive Plan featuring an evergreen provision for annual share increases.
🚩 Red Flags
- Extreme potential for dilution following a 4x increase in authorized shares.
- The 5% annual evergreen provision in the 2026 Incentive Plan provides significant long-term dilutive pressure.
- Approval for warrant and preferred stock conversions indicates a reliance on complex, potentially toxic, or highly dilutive financing structures.
📋 Key Facts
- Authorized common stock increased by 315%, from 68,343,750 to 283,757,150 shares.
- Stockholders approved the issuance of Common Stock upon conversion of Series B Preferred Stock and exercise of Series A, B, and C Warrants.
- The 2026 Incentive Plan was approved, initially reserving 6,407,374 shares plus an evergreen provision allowing for an annual increase of up to 5% of outstanding shares through 2036.
- The Increase in Authorized Shares Certificate of Amendment became effective on March 17, 2026.
Curis, Inc. has regained compliance with Nasdaq's Minimum Viable Listing Standard (MVLS) following a previous deficiency. However, the company is now subject to a one-year Discretionary Panel Monitor period.
🚩 Red Flags
- Subject to a one-year Discretionary Panel Monitor, indicating previous serious listing violations.
- Loss of standard 'cure' protections: any future deficiency during the monitor period could lead directly to a Delist Determination Letter without further grace periods.
📋 Key Facts
- On February 3, 2026, Nasdaq notified Curis, Inc. that it has regained compliance with Listing Rule 5550(b)(2).
- The company is in full compliance with the terms set forth by the Nasdaq Hearings Panel.
- Curis will be subject to a Discretionary Panel Monitor for a period of one year.
- Any further non-compliance during this monitoring period may lead to immediate delisting without the standard opportunity to provide a compliance plan or cure period.
Curis, Inc. entered into a PIPE financing agreement to issue Series B convertible preferred stock and multiple series of warrants (Series A, B, and C) to a group of purchasers including company executives. The deal is expected to raise up to $80.8 million in total gross proceeds, with an initial $20.2 million expected at closing.
🚩 Red Flags
- Significant dilution potential due to massive warrant coverage (over 26 million shares of common stock via each series).
- Related-party involvement: The offering includes the company's top executives (CEO, CFO, CMO, CDO) and a Board member as purchasers.
- Series B warrants contain a price reset mechanism if the stock price is below $0.75 at the time of a clinical milestone.
- The financing requires stockholder approval to enable conversion of preferred stock.
📋 Key Facts
- PIPE financing involves 20,195 shares of Series B convertible non-redeemable preferred stock.
- Warrants include Series A (terminating Jan 2031), Series B (linked to emavusertib Phase 2 trial milestone), and Series C (terminating July 2027).
- Initial gross proceeds at closing are expected to be approximately $20.2 million.
- Total potential gross proceeds reach ~$80.8 million assuming full warrant exercise.
- Warrant exercise price is set at $0.75 per share.
- Purchasers include the Company's CEO, CFO, CMO, CDO, and a Board member.
Curis, Inc. filed an amendment to its 8-K to provide pro forma financial information following the completed sale of its interest in Curis Royalty, LLC to TPC Investments Royalty LLC.
🚩 Red Flags
- Asset disposition: The company is selling off a royalty interest, which often indicates a need for immediate liquidity or a shift in corporate strategy/focus.
📋 Key Facts
- The filing is an Amendment (Form 8-K/A) to an original report dated November 6, 2025.
- Curis, Inc. completed the sale of its interest in Curis Royalty, LLC to TPC Investments Royalty LLC (managed by Oberland Capital Management, LLC).
- The amendment includes unaudited pro forma condensed consolidated balance sheet as of September 30, 2025.
- Includes unaudited pro forma statements of operations for the nine months ended Sept 30, 2025, and the year ended Dec 31, 2024.
Curis, Inc. has completed the sale of its interest in Curis Royalty (the 'Erivedge Business'), which includes all rights to royalties from Genentech's Erivedge. The company will no longer receive royalty revenues but will recognize a gain and extinguish related liabilities in Q4 2025.
🚩 Red Flags
- Loss of recurring revenue stream: The company is divesting its primary source of royalty income from Erivedge.
- Delisting Risk: Nasdaq has granted an exception to the Market Value Listing Standard (MVLS) only until November 14, 2025. This filing occurs just days before that deadline.
- Liquidity/Capitalization concerns: The company is selling core assets for a relatively small upfront amount ($2.5M) likely to clean up the balance sheet and address delisting requirements.
📋 Key Facts
- Sold the Erivedge Business (including intellectual property and License Agreement) to TPC Investments Royalty LLC on November 6, 2025.
- Transaction received upfront consideration of $2.5 million.
- The sale includes a release of the Company's liability related to the sale of future royalties to Oberland.
- Company will no longer be entitled to revenues under the Erivedge License Agreement (royalty rates were 5% to 7.5%).
- Expected to recognize a gain in its statement of operations and comprehensive loss in Q4 2025.
Curis, Inc. has been granted a temporary exception period by the Nasdaq Hearings Panel to regain compliance with the Minimum Market Value Listing Standard (MVLS). The company must meet the $35 million market value requirement by November 14, 2025.
🚩 Red Flags
- Failure to meet the $35 million Minimum Market Value Listing Standard (MVLS).
- Imminent deadline of November 14, 2025, to regain compliance.
- Nasdaq maintains discretion to reconsider and revoke the exception based on any significant event.
📋 Key Facts
- Nasdaq delisting notice was originally received on August 21, 2025, due to failure to meet Rule 5550(b)(2) (MVLS Requirement).
- The MVLS Requirement requires a minimum market value of $35,000,000.
- A hearing request was filed by the company, which stayed delisting actions.
- On October 20, 2025, Nasdaq granted an 'Exception Period' until November 14, 2025.
- The Panel reserves the right to revoke the exception if significant events occur that call into question continued listing.
Curis, Inc. has received a delisting notice from Nasdaq because it failed to regain compliance with the Minimum Market Value Listing Standard (MVLS) by the August 20, 2025 deadline. The company intends to appeal the decision via a hearing request to stay the delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(b)(2))
- Failure to meet minimum market value requirements ($35M threshold)
- Imminent threat of delisting from a major exchange
📋 Key Facts
- Nasdaq issued notice on August 21, 2025, due to failure to meet MVLS Requirement (Rule 5550(b)(2)).
- The company's market value was below $35,000,000 for the previous 30 consecutive trading days.
- The compliance period expired on August 20, 2025.
- The company must request a hearing before the Nasdaq Hearings Panel by August 28, 2025, to appeal.
- A timely appeal will stay the suspension and delisting of securities pending the panel's decision.
Curis, Inc. has filed a prospectus supplement under its existing S-3 shelf registration to offer up to $8,137,047 of common stock. This follows the company's July 2025 decision to terminate a much larger $100 million offering program.
🚩 Red Flags
- Significant reduction in offering size from $100M (terminated) to ~$8.1M suggests highly selective/limited capital needs or a shift in financing strategy.
- Continuous use of shelf registration for small amounts often indicates an ongoing need for immediate liquidity.
📋 Key Facts
- The company is offering up to $8,137,047 in common stock via a prospectus supplement.
- The offering is conducted under an existing S-3 shelf registration statement (File No. 333-276950) effective as of April 12, 2024.
- Agents for the sale are Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC.
- On July 1, 2025, the company terminated a prior prospectus related to an offering of up to $100 million.
Curis, Inc. filed an 8-K to announce its financial results for the three-month and six-month periods ending June 30, 2025. The filing serves as a formal notification that earnings data is being released via press release.
📋 Key Facts
- Reporting period: Three- and six-month periods ended June 30, 2025.
- Announcement date: August 5, 2025.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Curis, Inc. entered into a securities purchase agreement to conduct a $7.0 million registered direct offering and a concurrent private placement involving pre-funded warrants and common warrants. The deal includes significant warrant coverage and registration rights agreements with liquidated damages provisions.
🚩 Red Flags
- Significant warrant overhang: The number of shares issuable via warrants (3,076,921 common + 1,538,461 pre-funded) is significantly higher than the new shares being issued in the direct offering.
- Dilutive structure: The inclusion of numerous warrants at a fixed price ($2.15) can lead to significant dilution for existing shareholders upon exercise.
- Liquidated damages clause: The company must pay 1.0% liquidated damages per 30-day period if registration rights are not met, creating additional financial liability.
📋 Key Facts
- Aggregate gross proceeds expected to be approximately $7.0 million before fees.
- The offering consists of 1,538,460 shares of common stock in a registered direct offering.
- Concurrent private placement includes pre-funded warrants for up to 1,538,461 shares and unregistered warrants for up to 3,076,921 shares.
- Common Warrants have an exercise price of $2.15 per share and a term of five years.
- Pre-funded warrants have an exercise price of $0.01 per share.
- The combined purchase price for one Share and the associated Common Warrant is $2.275.
- Placement agents (Laidlaw & Company (UK) Ltd. and JonesTrading Institutional Services LLC) will receive approximately $0.5 million in cash fees plus expenses up to $0.1 million.
Curis, Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved several significant structural changes, including a massive increase in authorized shares and an expansion of the company's stock incentive plan.
🚩 Red Flags
- Significant increase in authorized shares often precedes dilutive equity offerings or warrants exercises.
- The massive expansion of authorized shares (from ~39M to ~73M) suggests a need for significant future capital raising via equity.
- Modification of quorum requirements to 1/3 may be intended to facilitate easier corporate actions with less shareholder participation.
📋 Key Facts
- Stockholders approved increasing authorized capital stock from 39,171,875 to 73,743,750 shares (a nearly 2x increase).
- The Fifth Amended and Restated 2010 Stock Incentive Plan was amended to reserve an additional 1,255,000 shares.
- Shareholders approved the issuance of up to 8,316,882 shares upon exercise of warrants from a March 31, 2025 private placement.
- The quorum requirement in the Bylaws was modified from a majority to one-third (1/3) of outstanding shares.
- PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2025.
Curis, Inc. filed an 8-K to announce its financial results for the three-month period ended March 31, 2025. The filing serves as a formal notification of the earnings release issued on May 6, 2025.
📋 Key Facts
- Reporting period: Three-month period ended March 31, 2025.
- Announcement date: May 6, 2025.
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Curis, Inc. filed an 8-K to announce its financial results for the three- and twelve-month periods ended December 31, 2024.
📋 Key Facts
- Reporting period: Three- and twelve-month periods ended December 31, 2024.
- Filing date: March 31, 2025.
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Curis, Inc. entered into a securities purchase agreement to conduct a combined registered direct offering and private placement of common stock and warrants. The offerings aim to raise approximately $10 million in gross proceeds from institutional investors.
🚩 Red Flags
- Significant potential dilution: The issuance of over 8 million warrants represents a massive increase in the potential common share count.
- Warrant overhang: Unregistered warrants are being issued to institutional investors, which can lead to immediate selling pressure upon exercise/registration.
- Liquidation damages clause: The company faces penalties (1.0% per 30-day period) if it fails to meet registration deadlines.
📋 Key Facts
- Total expected gross proceeds: ~$10.0 million (before fees).
- Registered Offering: 1,974,432 shares of common stock.
- Private Placement includes pre-funded warrants for up to 2,184,009 shares and unregistered warrants for up to 8,316,882 shares.
- Common Warrant exercise price: $2.41 per share; Pre-Funded Warrant exercise price: $0.01 per share.
- The offerings are expected to close on or before March 31, 2025.
- Laidlaw & Company (UK) Ltd. is acting as the sole placement agent.
- Registration Rights Agreement requires the company to file a registration statement for resale within 60 days of closing.
Curis, Inc. received a notice from Nasdaq stating it is non-compliant with the Minimum Market Value Listing Standard (MVLS) because its market value fell below $35 million for 30 consecutive business days. The company has until August 20, 2025, to regain compliance by maintaining a market value of at least $35 million for 10 consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq
- Market capitalization has fallen below the critical $35M threshold required by Nasdaq
- Risk of delisting if compliance is not met by August 20, 2025
📋 Key Facts
- Received notice from Nasdaq on February 21, 2025.
- Non-compliance with Nasdaq Listing Rule 5550(b)(2) (MVLS Requirement).
- Market value has been below $35,000,000 for the last 30 consecutive business days.
- Compliance period granted: 180 calendar days, expiring August 20, 2025.
- Requirement to regain compliance: Market value must close at $35,000,000 or more for a minimum of 10 consecutive business days.
Curis, Inc. filed an 8-K to announce its financial results for the three-month and nine-month periods ended September 30, 2024.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Three-month and nine-month periods ended September 30, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Curis, Inc. entered into a securities purchase agreement to conduct a registered direct offering and a concurrent private placement of unregistered warrants. The offerings aim to raise approximately $12.1 million in gross proceeds.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 2.3 million new shares and a matching number of warrants.
- Warrants are unregistered and include registration rights with liquidated damages provisions (1.0% per 30-day period) if registration is delayed.
- Cash runway is limited, extending only into mid-2025 based on current R&D plans.
📋 Key Facts
- Registered Direct Offering: 2,398,414 shares of common stock.
- Private Placement: Up to 2,398,414 unregistered warrants with an exercise price of $4.92 per share.
- Combined purchase price for one share and one warrant is $5.045.
- Expected gross proceeds: approximately $12.1 million (before fees).
- Warrants have a 5-year term and are exercisable immediately upon issuance.
- The company expects the net proceeds to fund operations into mid-2025.
Curis, Inc. filed an 8-K to announce its financial results for the three-month and six-month periods ending June 30, 2024.
📋 Key Facts
- Report date: August 1, 2024
- Reporting period: Three and six months ended June 30, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Curis, Inc. announced a strategic restructuring plan involving an approximate 30% workforce reduction to focus on high-priority combination clinical studies. The company also reported results from its 2024 Annual Meeting of Stockholders, including the approval of increased authorized share counts and stock incentive plans.
🚩 Red Flags
- Significant workforce reduction (30%) indicating cost-cutting measures.
- Potential liquidity risk: Forward-looking statements admit insufficient cash on hand to support current operations within the next 12 months without further funding.
- Strategic deprioritization of certain clinical programs/monotherapy studies.
📋 Key Facts
- Initiated a plan to streamline operations and reduce workforce by approximately 30%.
- Strategic pivot to focus on combination studies in relapsed/refractory primary CNS lymphoma (with ibrutinib) and front-line AML (with azacitidine and venetoclax).
- Stockholders approved increasing authorized shares from 27,781,250 to 39,171,875.
- Approved the Fifth Amended and Restated 2010 Stock Incentive Plan, adding 942,100 shares.
- Cash runway is stated to support operations into 2025, though forward-looking statements note a lack of sufficient cash on hand for current operations within the next 12 months without additional funding.
Curis, Inc. announced updated clinical data from its TakeAim Leukemia study (CA-4948-102) regarding emavusertib monotherapy in patients with R/R AML. The update includes expanded cohorts for FLT3 mutation and SFm mutations to be presented at upcoming medical conferences.
🚩 Red Flags
- Going concern warning: The company stated, 'Based on its available cash resources, it does not have sufficient cash on hand to support current operations within the next 12 months.'
- Heavy dependence on the success of a single drug candidate (emavusertib).
📋 Key Facts
- Updated data from TakeAim Leukemia study (CA-4948-102) involves 25 new patients in the FLT3m and SFm cohorts.
- FLT3m Cohort: 12 total R/R AML patients treated; 6 objective responses in 11 response-evaluable patients (including 3 CR, 1 CRh, and 2 MLFS).
- SFm Cohort: 20 total R/R AML patients treated; 4 objective responses in 18 response-evaluable patients.
- All responders across both cohorts demonstrated complete normalization of blast counts in the bone marrow.
- The company explicitly states it does not have sufficient cash on hand to support current operations within the next 12 months.
Curis, Inc. filed an 8-K to announce its financial results for the three-month period ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via press release.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Announcement date: May 7, 2024.
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial results.
Curis, Inc. filed an 8-K to announce its financial results for the full year and quarter ended December 31, 2023. The filing serves as a formal wrapper for the press release containing the company's latest operational and financial performance data.
📋 Key Facts
- Reported date: February 8, 2024
- Period covered: Full year and quarter ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 containing the detailed financial results.
Curis, Inc. filed an 8-K to provide a copy of its current corporate slide presentation used in meetings with third parties. This is a standard regulatory filing under Item 7.01 (Regulation FD Disclosure) and does not contain material changes to business operations or financial position.
📋 Key Facts
- The company provided an updated corporate slide presentation as Exhibit 99.1.
- The disclosure is intended to satisfy Regulation FD requirements during third-party meetings.
- Filed on January 11, 2024.